Agenda and Abstracts
Thursday
November 30, 2000
Introductory Session
|
| 19:00
20:00
|
Reception
How Do We Die -- Markers or Mediators? William Lands, PhD
|
| 20:30 |
Diabetes in Native Americans: Dietary Approaches to Reducing CVD Risk
Sven Ebbesson, PhD |
| 21:00 |
The GISSI Prevention Study: Principal Findings
Roberto Marchioli, MD |
|
Friday
December 1, 2000
|
| 8:00 |
Welcome
William Harris, PhD |
|
Session 1: Omega-3 FAs and CV Events in Diabetic Patients: Clinical
Trial and Epidemiologic
Evidence
Chairs: Roberto Marchioli, MD and David Siscovick,
MD
|
| 8:10
|
Effects of w3 FAs in Diabetic Patients in the GISSI Prevention Study
Roberto Marchioli, MD |
| 8:30 |
Epidemiologic Evidence for a Protective Effect of Fish in Diabetic Patients
Martha Daviglus, MD, PhD |
| 8:50
|
Prevention of Sudden Death By Low Intakes of w3 FAs
David Siscovick, MD |
| 9:10 |
Discussion and Questions
Session Chairs |
|
Session 2: Diabetes and CV Disease: Magnification of Risk
Chairs: Steven Haffner, MD and James O-Keefe, MD
|
| 9:30
|
Diabetes As a Risk Factor for CHD
Steven Haffner, MD |
| 9:50 |
Diabetes,
Lipoproteins, and Atherosclerosis
Henry Ginsberg, MD |
| 10:10 |
Break |
| 10:30
|
Hemostatic Abnormalities in Type 2 Diabetes
Norberta Schoene, PhD |
| 10:50
|
Alterations in Blood Pressure and Endothelial Function in Types 2 Diabetes
James Sowers, MD |
| 11:10
|
Diabetes and Autonomic Dysfunction: a Cause for Increased CHD Risk?
James O'Keefe, MD |
| 11:30 |
Discussion and Questions
Session Chairs |
| 11:45 |
Lunch |
|
Session 3: Effects of w3 FAs on Insulin and
Glucose Metabolism: Basic Science
Chairs: Leonard Storlien, PhD and John Miles, MD
|
|
12:40
|
Fundamentals of Carbohydrate and Lipid Metabolism in Diabetes
John Miles, MD |
| 13:00 |
Insulin
Resistance and w3 FAs: Animal and Cell Culture
Michael Clandinin, PhD
|
| 13:20 |
Insulin
Resistance and w3 FAs: Human
William L. Isley, MD |
| 13:40 |
w3
FAs and Expression of Genes of Lipid Metabolism
James Ntambi, PhD |
| 14:00 |
PPAR,
SREBP and w3 FAs
Donald Jump, PhD
|
| 14:20 |
Discussion and Break |
|
Session 4: Effects of w3
FAs on Insulin and Glucose Metabolism: Safety Issues
Chair: William Connor, MD |
| 15:00 |
Historical
Concerns Regarding the Use of w3 FAs in Diabetic
Patients
Bengt Vessby, MD |
| 15:20 |
Multicenter
Trial of w3 Fatty Acids in Type 2 Diabetic
Patients
Angela Rivellese, MD |
| 15:40 |
Diabetic
Control is Not Adversely Affected by w3 FA
Supplementation
William Connor, MD |
| 16:00 |
Glycemic
Control and Marine w3 FAs: A Meta-Analysis
Mark Deeg, MD |
| 16:20 |
Discussion and Questions
Session Chairs |
|
Session 5: Effects of w3 FAs on Risk Factors for CV
Disease: Vascular Biology and Blood Pressure
Chairs: Christine Ballantyne, MD and Clemens von Schacky, MD
|
| 16:40 |
Circulating
Adhesion Molecules and w3 FAs
Christine Ballantyne, MD
|
|
| 17:00 |
Effects
of w3 FAs on Blood Pressure
Trevor Mori, PhD
|
|
| 17:20 |
Fish
Oils and Blood Pressure in Diabetic Patients
Ingrid Toft, MD, PhD
|
|
| 17:40 |
Discussion and Questions
|
|
| 18:00 |
Adjourn
|
|
| 19:00 |
Conference Dinner and Special Program
|
|
|
Saturday
December 2, 2000
|
|
| 07:00 |
Breakfast
|
|
| |
Session 5 (continued): Effects of w3 FAs on Risk
Factors for CV Disease: Vascular Biology and Blood Pressure
Chairs: Christine Ballantyne, MD and Clemens von Schacky, MD
|
|
| 08:00 |
Modulation
of Endothelial Health by w3 FAs
Gary McVeigh, MD
|
|
| 08:20 |
Diminishing
Inflammatory Responses With w3 FAs
Clemens von Schacky, MD
|
|
| 08:40 |
Discussion and Questions
Session Chairs
|
|
|
Session 6: Effects of w3 FAs on Risk Factors for CV
Disease: Lipoprotein Metabolism and Platelet Function
Chairs: Ernst Schaefer, MD and Howard Knapp, MD, PhD
|
|
| 08:50 |
High
Fish Diets and Remnant Lipoprotein
Ernst Schaefer, MD
|
|
| 09:10 |
Effects
of w3 FAs on LDL-Cholesterol in Diabetes
William Harris, PhD
|
|
| 09:30 |
Omega-3
Fatty Acids in the Treatment of the Atherogenic Lipoprotein Phenotype
Christine Williams, PhD
|
|
| 09:50 |
Break
|
|
| 10:10 |
Omega-3
Fatty Acids and Statins: Combined Therapy for Dyslipidemia
Arne Nordoy, MD
|
|
| 10:30 |
Overview
of the w3 FAs, Hemostasis and Diabetes
Howard Knapp, MD, PhD
|
|
| 10:50 |
Discussion and Questions
Session Chairs
|
|
|
Session 7: Effects of w3 FAs on Excitable Membranes:
Implications for Diabetes
Chair: Alexander Leaf, MD
|
|
| 11:10 |
Can
w3 FAs Improve Heart Rate Variability?
Erik Berg Schmidt, MD
|
|
| 11:30 |
Omega-3
Fatty Acids and Arrhythmias: Animal Studies
Peter McLennan, PhD
|
|
| 11:50 |
Altering
Metabolic Function of Excitable Tissues With w3
FAs
Alexander Leaf, MD
|
|
| 12:10 |
Discussion and Questions
|
|
| 12:30 |
Lunch
|
|
|
Session 8: Nutritional Issues
Chair: Artemis Simopoulos, MD
|
|
| 13:20 |
Evolutionary
aspects of w3 FA intake
Artemis Simopoulos, MD
|
|
| 13:40 |
Incorporating
w3 FAs into diabetic diets
Sonja Connor, MS, RD
|
|
|
Summary, Conclusions and Recommendations
Chairs: William Harris, John Miles, James O'Keefe, Artemis Simopoulos,
Robert Katz
|
|
| 14:00 |
Group Discussion of the following questions (addressed in working lunches)
- Does it appear likely that up to 3 g of w3 FAs
will materially reduce CVD risk in diabetes?
- Are there significant safety concerns regarding the use of up to 3 g
of w3 FAs/day in patients with type 2 diabetes?
- Is it time for a major clinical trial to test the hypothesis that w3
fatty acids can reduce CV events in patients with type 2 diabetes?
€ If yes, how should it be designed?
€ If no, what additional studies are
needed?
|
|
| 15:30 |
Closing Remarks
|
|